Impact of genetic diagnostics on drug development strategy.
Innovation in diagnostics will be essential for the successful adoption of personalized medicine and will also have a major impact on the success of drug development strategies. To remain competitive, companies will need to embrace the rapid innovation in the diagnostic market, utilize diagnostic tools concurrently with research and development, and re-invent how new drugs are brought to market. In this article, specific examples of targeted oncology drugs are used to illustrate the general impact of genetic diagnostics on drug development.
Million
Ryan P
RP
Trinity Partners, LLC, 100 Park Avenue, Suite 1600, New York, New York 10017, USA. rmillion@trinitypartners.com
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000069439:Dasatinib; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D000077156:Gefitinib; D005820:Genetic Testing; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics; D010597:Pharmacogenetics; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011743:Pyrimidines; D011799:Quinazolines; D013844:Thiazoles; D000069439:Dasatinib; D000077156:Gefitinib